Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis

Author: Roblin David   Yosipovitch Gil   Boyce Brent   Robinson John   Sandy James   Mainero Valentina   Wickramasinghe Ro   Anand Uma   Anand Praveen  

Publisher: Medical Journals Limited

E-ISSN: 1651-2057|95|5|542-548

ISSN: 0001-5555

Source: Acta Dermato-Venereologica, Vol.95, Iss.5, 2015-05, pp. : 542-548

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content